Speakers - Sachs Associates

More documents

Recommendations

Info

CONTACT Stavros Therianos (speaker) Chief Executive Officer ADDRESS Chemin de la Vuillette 4 CH-1000 Lausanne 25 Switzerland TELEPHONE +41 21 989 2000 FAX +41 21 989 2001 EMAIL stherianos@diagnoplex.com YEAR FOUNDED 2005 Diagnoplex SA www.diagnoplex.com FINANCIAL SUMMARY CHF 15 million in series “A” COMPANY PROFILE We are a dedicated and multi-disciplinary team united in bringing true innovation to personalized cancer care. Using our unique molecular workflow and state-of-the-art biostatistical tools, we develop blood-based cancer diagnostic tests. Our initial focus is on systematic screening for colorectal cancer. This is an area of increasingly urgent and unmet medical need as a result of an ageing population, and one that represents an estimated market opportunity of $3.5 billion. Diagnoplex lead product, Colox, is a convenient and non-invasive blood test developed for the systematic screening of colorectal cancer (Colorectal cancer). The gene signature underlying Colox detects early and advanced disease stages with outstanding results and reliability. SCIENTIFIC FOCUS Cancer, RNA Therapeutics, Preclinical MANAGEMENT Lothar Wieczorek, Ph.D., Executive Chairman Lothar Wieczorek has been at the forefront of the development of medical devices and products in the US and European Pharmaceutical and Diagnostics industries throughout his 30-year career, where he has held senior positions in R&D, Business Development, Strategic Planning and Medical Affairs. Stavros Therianos, Ph.D. Chief Executive Officer Stavros Therianos is one of the principal founders of Diagnoplex and has been with the company since 2005. Stavros is a consummate entrepreneur who brings his talent and passion to Diagnoplex science and business activities. Prior to the founding of Diagnoplex, he was an assistant professor at the University of Rochester Medical Center, USA. t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
CONTACTS Ana Martinez Assistant Juan Ruiz Chief Operating Officer and Chief Medical Officer Fernando Terron Business Development ADDRESS Avda Pio XII, 22 Office 2 CP 31008 Pamplona. Navarra Spain TELEPHONE +34 94 828 7600 FAX +34 94 818 0500 EMAIL amartinez@dignabiotech.com jruiz@dignabiotech.com fterron@biolty.com YEAR FOUNDED 2004 Digna Biotech, S.L. www.dignabiotech.com FINANCIAL SUMMARY Capital raised to date in excess of 30 M€. Currently interested in raising an additional 20 M€ COMPANY PROFILE DIGNA Biotech is a private biotechnology company headquartered in Pamplona (Spain), with offices in Madrid and Pennsylvania (USA). It was founded in 2004 as a spin-off of the University of Navarra. The firm currently has a pipeline of 9 products at different stages of development in 3 therapeutic areas: Inflammatory/Autoimmune, Cardiovascular and Liver diseases. Digna Biotech is seeking private funding to spin out a new biotech company to conduct Phase IIb and Phase III trials of its more advanced candidate, a cytokine inhibitor for the treatment of patients with Systemic Sclerosis and Localized Scleroderma. The product (Disitertide) has already completed Phase I, Phase IIa and open-label extension (OLE) clinical trials under a topical formulation in patients with systemic sclerosis. Orphan drug designation by both FDA and EMA has been granted in the two indications. MANAGEMENT Pablo Ortiz, MD, PhD, CEO. – (portiz@dignabiotech.com) t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2: B I O T E C H I N E U R O P E I N V
Page 3 and 4: Events Diary For regular updates, s
Page 5 and 6: Speakers Alexey Eliseev, Managing D
Page 7 and 8: Speakers Blake M. Paterson, Co-Foun
Page 9 and 10: Speakers David Slack, Head of Corpo
Page 11 and 12: Speakers Frank Grams, VP, Head Alli
Page 13 and 14: Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16: Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18: Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20: Speakers Paul Higham, Managing Dire
Page 21 and 22: Speakers Richard Goodfellow, CEO, S
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49: CONTACT Barbara Stiefel Office Mana
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70: CONTACT Tom Johnston Chief Executiv
Page 71 and 72: CONTACTS Aaron Powers President Dav
Page 73 and 74: CONTACTS General and Media Contact
Page 75 and 76: CONTACTS Martin Welschof Chief Exec
Page 77 and 78: CONTACTS Carlos Buesa Chief Executi
Page 79 and 80: CONTACTS Nick McCooke Chief Executi
Page 81 and 82: CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84: CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86: CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88: ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90: CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92: CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94: CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96: CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98: CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100: CONTACTS Piers Morgan Chief Financi
Page 101 and 102:
CONTACT Jakob Knudsen Chief Executi
Page 103 and 104:
CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106:
Supporting Organisations Citigate D
Page 107 and 108:
Supporting Organisations Life Scien
Page 109 and 110:
Supporting Organisations Swiss Biot
Page 111 and 112:
Supporting Organisations Torreya Pa
Page 113:
B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?